Clinical trialNCT06055439RecruitingPhase 1/PHASE2Interventional

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

SponsorChimeric TherapeuticsEnrollment135Colorectal CancerGastric CancerNeuroendocrine Tumors

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least 1 standard treatment regimen in the metastatic or locally advanced setting.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Jennifer Eads, MD
University of Pennsylvania
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Emory University
Atlanta, Georgia, United States
Daniel M Halperin, MD
Recruiting
University of Chicago
Chicago, Illinois, United States
Daniel Olson, MD
Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Jennifer Eads, MD
Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Meredith Pelster, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CHM-2101 CAR-T cells

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 15 May 2024
Primary completion: 31 May 2026
Completion: 31 May 2027
Last update posted: 29 Jan 2026
Registered enrollment: 135
Registry id: NCT06055439

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.